During the COVID-19 pandemics of 2020, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), both adults and children were shown to mount a specific antibody response to the virus. As infected children often exhibit mild symptoms or even remain asymptomatic, they are likely to be under tested for the direct presence of the virus. Mapping the SARS-CoV-2 antibodies frequency informs more accurately on the disease prevalence and helps guide the protective and therapeutic strategies. To date, only few seroprevalence studies included children. In the Czech Republic, in April 2020, the overall SARS-CoV-2 seroprevalence was estimated not to exceed 1.3%. In July and August, 2020, we screened 200 children (0-18 years of age), who attended the pediatric department of a large hospital in Prague for various COVID-19-unrelated reasons, for the presence of SARS-CoV-2 antibodies. Zero seropositive subjects were found. Therefore, we hereby report a low (<0.5%) seroprevalence amongst children in Prague, as of August, 2020.

Department of Clinical Chemistry Thomayer's Hospital Prague Czechia

Department of Immunology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Pediatrics 1st Faculty of Medicine Charles University and Thomayer's Hospital Prague Czechia

Department of Pediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Czechia

Laboratory of Immunology Thomayer's Hospital Prague Czechia

Zobrazit více v PubMed

COVID-19 Prehled aktuální situace v CR (COVID-19 Overview of Current Situation in the Czech Republic. 2020). (2020). Available online at: https://onemocneni-aktualne.mzcr.cz/covid-19 (accessed August 8, 2020).

European Center for Disease Control (2020). Available online at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases (accessed August 8, 2020).

Wu X, Fu B, Chen L, Feng Y. Serological tests facilitate identification of asymptomatic SARS-CoV-2 infection in Wuhan, China. J Med Virol. (2020). 20:10. 10.1002/jmv.25904 PubMed DOI PMC

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med. (2020) 382:1663–5. 10.1056/NEJMc2005073 PubMed DOI PMC

Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. (2020) 396:535–44. 10.1016/S0140-6736(20)31483-5 PubMed DOI PMC

Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics. (2020) 145:e20200702. 10.1542/peds.2020-0702 PubMed DOI

Liu P, Cai J, Jia R, Xia S, Wang X, Cao L, et al. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19. Emerg Microbes Infect. (2020) 9:1254–8. 10.1080/22221751.2020.1772677 PubMed DOI PMC

Hua CZ, Miao ZP, Zheng JS, Huang Q, Sun QF, Lu HP, et al. Epidemiological features and viral shedding in children with SARS-CoV-2 infection. J Med Virol. (2020) 92:2804–12. 10.1002/jmv.26180 PubMed DOI PMC

To KK, Tsang OT, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. (2020) 20:565–74. 10.1016/S1473-3099(20)30196-1 PubMed DOI PMC

Health Information and Quality Authority Evidence Summary of the Immune Response Following Infection with SARS- CoV-2 or Other Human Coronaviruses Available online at: https://www.hiqa.ie/sites/default/files/2020-06/Evidence-summary_SARS-CoV-2-immune-response.pdf (accessed August 8, 2020).

Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. (2020) 26:1200–4. 10.1038/s41591-020-0965-6 PubMed DOI

Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliott J, Hofmann C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild covid-19. N Engl J Med. (2020) 383:1085–7. 10.1056/NEJMc2025179 PubMed DOI PMC

Seow J, Graham C, Merrick B, Acors S, Steel KJA, Hemmings O, et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. medRxiv. (2020). 10.1101/2020.07.09.20148429 DOI

Sariol A, Perlman S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity. (2020) 53:248–63. 10.1016/j.immuni.2020.07.005 PubMed DOI PMC

Snoeck CJ, Vaillant M, Abdelrahman T, Satagopam VP, Turner JD, Beaumont K, et al. Prevalence of SARS-CoV-2 infection in the Luxembourgish population the CON-VINCE study. medRxiv. (2020). 10.1101/2020.05.11.20092916 DOI

Shakiba M, Hashemi Nazari SS, Mehrabian F, Rezvani SM, Ghasempour Z, Heidarzadeh A. Seroprevalence of COVID-19 virus infection in Guilan province, Iran. medRxiv. (2020). 10.1101/2020.04.26.20079244 PubMed DOI PMC

Doi A, Iwata K, Kuroda H, Hasuike T, Nasu S, Kanda A, et al. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: a cross-sectional study. medRxiv. (2020). 10.1101/2020.04.26.20079822 PubMed DOI PMC

Dusek L. (2020). Available online at: https://covid-imunita.uzis.cz/res/file/prezentace/20200506-dusek.pdf (accessed August 8, 2020).

Elecsys Anti-SARS-CoV-2. Package Insert 2020-07, V3.0. Material Numbers 09203095190 and 09203079190.

EUROIMMUN Anti-SARS-CoV-2 ELISA IgA, Package Insert. EI_2606A_A_US_C01.docx Version: 2020-03-24.

EUROIMMUN Anti-SARS-CoV-2 ELISA IgG, Package Insert. EI_2606G_A_US_C02.docx Version: 2020-05-04.

Hörber S, Soldo J, Relker L, Jürgens S, Guther J, Peter S, et al. Evaluation of three fully-automated SARS-CoV-2 antibody assays. Clin Chem Lab Med. (2020). 10.1515/cclm-2020-0975. [Epub ahead of print]. PubMed DOI

Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. (2020) 396:313–9. 10.1016/S0140-6736(20)31304-0 PubMed DOI PMC

Herzog S, de Bie J, Abrams S, Wouters I, Ekinci E, Patteet L, et al. Seroprevalence of IgG antibodies against SARS coronavirus 2 in Belgium: a prospective cross-sectional study of residual samples. medRxiv. (2020). 10.1101/2020.06.08.20125179 PubMed DOI PMC

Bobrovitz N, Arora RK, Yan T, Rahim H, Duarte N, Boucher E, et al. Lessons from a rapid systematic review of early SARS-CoV-2 serosurveys. medRxiv. (2020). 10.1101/2020.05.10.20097451 DOI

Dingens AS, Crawford KHD, Adler A, Steele SL, Lacombe K, et al. Seroprevalence of SARS-CoV-2 among children visiting a hospital during the initial seattle outbreak. medRxiv. (2020). 10.1101/2020.05.26.2011412 PubMed DOI PMC

Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, et al. Estimating the burden of SARS-CoV-2 in France. Science. (2020) 369:208–11. 10.1126/science.abc3517 PubMed DOI PMC

Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. SSRN Electron J. medRxiv. (2020). 10.1101/2020.03.30.20047365 DOI

Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission and control of COVID-19 epidemics. Nat Med. (2020) 26:1205–11. 10.1038/s41591-020-0962-9 PubMed DOI

Nickbakhsh S, Ho A, Marques DFP, McMenamin J, Gunson RN, Murcia PR. Epidemiology of seasonal coronaviruses: establishing the context for the emergence of coronavirus disease 2019. J Infect Dis. (2020) 222:17–25. 10.1093/infdis/jiaa185 PubMed DOI PMC

Bunyavanich S, Do A, Vicencio A. Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. JAMA. (2020) 323:2427–9. 10.1001/jama.2020.8707 PubMed DOI PMC

Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg. (2019) 23:50–74. 10.1177/1203475418811335 PubMed DOI PMC

Beigel F, Schnitzler F, Paul Laubender R, Pfennig S, Weidinger M, Göke B, et al. Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease. Inflamm Bowel Dis. (2011) 17:91–8. 10.1002/ibd.21362 PubMed DOI

SARS-CoV-2 Specific Humoral Immune Responses after BNT162b2 Vaccination in Hospital Healthcare Workers